Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030


Barley Flakes Market Growth & Trends

The global barley flakes market size is expected to reach USD 10.83 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.0% from 2025 to 2030. Rising demand for the nutritious breakfast cereals among health conscious consumers, particularly youth population is expected to be a key driving factor for the barley flakes industry growth over the forecast period. Moreover, excellent nutritional properties, coupled with the ease of cooking associated with flakes, are projected to prompt the product consumption among the working class population over the next few years.

Organic flakes are expected to expand at the fastest CAGR of 4.6% from 2019 to 2025 in terms of volume. Governments of various developed as well as developing countries are taking initiatives to promote the organic crop through incentive and stringent government policies. According to a statistics (January 2019) provided by the European Commission, 12.6 million hectares of the land, which is equal to the 7% of the total agricultural land in Europe, was used for the certified organic farming in 2017.

In addition, manufacturers are launching new organic products in order to cater to needs of the health conscious customers. For instances, in January 2018, Rude Health, a U.K. based cereals and drinks manufacturer, launched organic breakfast cereal under the brand name ‘Naked Barley Porridge’. These government initiatives as well as new product launches are expected to expand the scope of organic product forms in the near future.

Over the past few years, the manufacturers have been launching new products in developing countries including China and India as a result of rising demand for nutritious on-the-go cereal meals among health conscious customers. For instance, in December 2018, Cosmic Nutracos Solutions Private Limitedlaunched a new product, Oats Multigrain in India under the brand name ‘Gaia’. The product contains a mix of barley flakes, oats, and rolled wheat, which is beneficial for weight management.

Barley Flakes Market Report Highlights
  • The conventional segment dominated the global market, with the largest revenue share of 73.8% in 2024. Conventional barley flakes are widely recognized and trusted by consumers for their nutritional benefits and versatility in various culinary applications.
  • The supermarket/hypermarket segment dominated the market with the largest revenue share of 63.2% in 2024. Supermarkets and hypermarkets provide a wide variety of products, allowing consumers to conveniently compare and choose from numerous brands.
  • Europe dominated the global barley flakes market, with a revenue share of 32.2% in 2024. Increasing consumer awareness about the health benefits of barley, such as its high fiber content and low glycemic index, has boosted demand.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mode of Administration
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of erectile dysfunction
3.2.1.2. Rising geriatric population
3.2.1.3. Increasing research & development (R&D)
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of healthcare infrastructure and manufacturing errors
3.2.2.2. Lack of awareness about erectile dysfunction
3.3. Erectile Dysfunction Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Erectile Dysfunction Drugs Market: Product Movement Analysis
4.3. Erectile Dysfunction Drugs Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Viagra (sildenafil citrate)
4.5.1. Viagra (sildenafil citrate) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Cialis (Tadalafil)
4.6.1. Cialis (Tadalafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Stendra/Spedra (avanafil)
4.7.1. Stendra/Spedra (avanafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Zydena (udenafil)
4.8.1. Zydena (udenafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Other Drugs
4.9.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Erectile Dysfunction Drugs Market: Mode of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Erectile Dysfunction Drugs Market: Mode of Administration Movement Analysis
5.3. Erectile Dysfunction Drugs Market by Mode of Administration Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Oral Mode of Administration
5.5.1. Oral Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Injectable Mode of Administration
5.6.1. Injectable Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Modes of Administration
5.7.1. Other Modes of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Recent Developments & Impact Analysis by Key Market Participants
7.3. Company Market Share Analysis, 2024
7.4. Key Company Profiles
7.4.1. Bayer AG
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Lilly
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. GlaxoSmithKline PLC
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Petros Pharmaceuticals, Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Pfizer Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Teva Pharmaceutical Industries Ltd
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Lupin Limited
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Futura Medical
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Cure Pharmaceutical
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. 23andMe
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Hims & Hers Health, Inc.
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. RO
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. BlueChew
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. GoodRx, Inc.
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings